Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884363 | 0.98 | FFAR4 (0.54) | FFAR4KEAP1TDP1FFAR1HDAC3 | |
| Hydrochloric Acid SCHEMBL7690739 | 0.98 | FFAR4 (0.54) | FFAR4KEAP1TDP1FFAR1HDAC3 | |
| SCHEMBL3884361 | 0.96 | FFAR4 (0.52) | FFAR4KEAP1TDP1FFAR1HDAC3 | |
| SCHEMBL8531827 | 0.96 | FFAR4 (0.52) | FFAR4KEAP1TDP1FFAR1HDAC3 | |
| SCHEMBL8531664 | 0.93 | FFAR4 (0.51) | FFAR4KEAP1TDP1FFAR1HDAC3 | |
| SCHEMBL5639162 | 0.88 | LMNA (0.58) | FFAR4KEAP1TDP1FFAR1HDAC3 | |
| SCHEMBL709431 | 0.86 | FFAR1 (0.57) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL13886133 | 0.85 | MAPT (0.59) | TDP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL18657103 | 0.84 | FFAR1 (0.63) | FFAR4FFAR1 | |
| SCHEMBL22266205 | 0.84 | LMNA (0.53) | FFAR4KEAP1TDP1FFAR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111187675-B | Method for determining feeding ratio and distillation time of Rosa damascena | 北京市农林科学院 | 2022-11-25 | — | — | CN | claimed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | HOFFMAN-LA ROCHE INC | 2007-11-29 | — | — | US | disclosed |
| WO-2007134986-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007121471-A2 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
| US-6727229-B2 | MACROLIDE ANTIBIOTICS PLAY A THERAPEUTICALLY IMPORTANT ROLE, PARTICULARLY WITH THE EMERGENCE OF NEW PATHOGENS | ENANTA PHARMACEUTICALS, INC. | 2004-04-27 | — | — | US | disclosed |
| WO-2004016634-A1 | Novel 11,12-Substituted Lactone Ketolide Derivatives Having Antibacterial Activity | ENANTA PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-4649160-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | FFAR4 44/4885KEAP1 3140/4885TDP1 3252/4885 |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | FFAR4 3167/4885KEAP1 1490/4885TDP1 277/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | FFAR4 4343/4885KEAP1 419/4885TDP1 1056/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | FFAR4 3167/4885KEAP1 1490/4885TDP1 277/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | FFAR4 3167/4885KEAP1 1490/4885TDP1 277/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | FFAR4 3167/4885KEAP1 1490/4885TDP1 277/4885 |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | GPR119, HCAR1, GPR84 | FFAR4 67/4885KEAP1 833/4885TDP1 1865/4885 |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | CYP51A1, SI, VIP | FFAR4 786/4885KEAP1 607/4885TDP1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.